Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas
- 20 October 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 73 (16) , 1273-1279
Abstract
Objective: To describe the characteristics of children enrolled in treatment trials for neurofibromatosis type 1 (NF1)–related plexiform neurofibroma (PN), PN tumor burden, PN-related complications, and treatment outcomes and to highlight the differences between characteristics of children with NF1 vs children with cancers entered on early phase drug trials. Methods: Pre-enrollment characteristics and complications of PN were retrospectively analyzed in a cohort of 59 children with NF1-related PN treated on 1 of 7 clinical trials at the NIH between 1996 and 2007. Outcome was analyzed in a subset of 19 patients enrolled in phase I trials. Comparisons to children with cancer were made from a similar analysis performed recently. Results: The median age at enrollment was 8 years. The median PN volume was 555 mL. Most patients had no prior chemotherapy or radiation, but nearly half had previous surgery for PN. PN-associated complications and NF1 manifestations were common, including pain (53%), other tumors (18%), and hypertension (8%). Investigational drug therapy was well tolerated. A median of 10 treatment cycles was administered. Patients with NF1-related PN were younger, had better performance score, had less prior therapy, and remained on study longer than cancer patients. Conclusions: Children with NF1-related plexiform neurofibroma (PN) enrolled in clinical trials had large tumors with substantial morbidity. Clinical trials in these children provide information about drug tolerance, cumulative toxicity, and pharmacokinetics in a younger population than early phase pediatric cancer trials. This report may aid in the evaluation of the applicability of traditional pediatric cancer trial designs and endpoints for NF1-related PN.Keywords
This publication has 22 references indexed in Scilit:
- Tumor Burden in Patients with Neurofibromatosis Types 1 and 2 and Schwannomatosis: Determination on Whole-Body MR ImagesRadiology, 2009
- Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology TrialsThe Oncologist, 2008
- Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- Phase I Trial of Pirfenidone in Children with Neurofibromatosis 1 and Plexiform NeurofibromasPediatric Neurology, 2007
- Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1Neurology, 2005
- Renovascular disease and hypertension in children with neurofibromatosisPediatric Nephrology, 2000
- Angiogenesis and Bone GrowthTrends in Cardiovascular Medicine, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Prognostic signs in the surgical management of plexiform neurofibroma: The Children’s Hospital of Philadelphia experience, 1974-1994The Journal of Pediatrics, 1997
- National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987.1988